Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Imricor Medical SystemsASX:IMR -1.33%42 Equity-to-Asset is 0.25 as of Dec. 2025, which is 59% below its 10-year median of 0.61. GuruFocus rates ASX:IMR with a GF Score™ of 42/100 and a GF Value™ of A$0.10 (Significantly Overvalued). The stock has 10 warning signs investors should review. Among 853 Medical Devices & Instruments companies, Imricor Medical Systems ranks worse than 86.75% on this metric.
The historical rank and industry rank for Imricor Medical Systems's Equity-to-Asset or its related term are showing as below:
ASX:IMR'
s Equity-to-Asset Range Over the Past 10 Years
Min: -1.05 Med: 0.61 Max: 0.86
Current: 0.25
During the past 8 years, the highest Equity to Asset Ratio of Imricor Medical Systems was 0.86. The lowest was -1.05. And the median was 0.61.
ASX:IMR's Equity-to-Asset is ranked worse than 86.75% of 853
companies
in the Medical Devices & Instruments industry
Industry Median: 0.64
vs ASX:IMR: 0.25
Imricor Medical Systems (ASX:IMR) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Imricor Medical Systems Equity-to-Asset Related Terms
Imricor Medical Systems Equity-to-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:IMR vs ABT, SYK, MDT: Equity-to-Asset Comparison
For the Medical Devices subindustry, Imricor Medical Systems's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Imricor Medical Systems Equity-to-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Imricor Medical Systems's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Imricor Medical Systems's Equity-to-Asset falls into.
Imricor Medical Systems Equity-to-Asset Calculation
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Imricor Medical Systems's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Imricor Medical Systems (ASX:IMR) has a Equity-to-Asset of 0.25 as of Dec. 2025. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Imricor Medical Systems and its competitors. This is 59% below median its historical median of 0.61. According to the industry distribution chart, Imricor Medical Systems ranks #740 out of 853 companies in the Medical Devices & Instruments industry, placing it in the top 86.8%.
Is Imricor Medical Systems' Equity-to-Asset too high?
Imricor Medical Systems' current Equity-to-Asset of 0.25 is 59% below median its 10-year median of 0.61. The Medical Devices & Instruments industry median Equity-to-Asset is 0.64. Imricor Medical Systems' value of 0.25 is 60.9% below this industry median. Based on the distribution chart, Imricor Medical Systems ranks #740 out of 853 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Imricor Medical Systems has a GF Score™ of 42/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Imricor Medical Systems' Equity-to-Asset compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Imricor Medical Systems ranks #740 out of 853 companies for Equity-to-Asset. This places Imricor Medical Systems in the lower half of its industry. The industry median Equity-to-Asset is 0.64. Imricor Medical Systems' value of 0.25 is 60.9% below this benchmark. While the company's 10-year median is 0.61 vs. the industry median of 0.64, Imricor Medical Systems has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Medical Devices & Instruments company?
The median Equity-to-Asset among Medical Devices & Instruments companies is 0.64, based on 853 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Imricor Medical Systems's current Equity-to-Asset of 0.25 is 60.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Imricor Medical Systems and its competitors. For the Medical Devices & Instruments industry, the median Equity-to-Asset is 0.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Imricor Medical Systems's current Equity-to-Asset is 0.25, which is 59% below median its own 10-year median of 0.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Imricor Medical Systems stock overvalued right now?
Based on GuruFocus' analysis, Imricor Medical Systems (ASX:IMR) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.10, compared to a current price of A$1.86 — trading 1760% above its estimated fair value. The current Equity-to-Asset is 0.25, which is 59% below median its 10-year median of 0.61 and 60.9% below the Medical Devices & Instruments industry median of 0.64. Imricor Medical Systems' overall GF Score™ is 42/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Imricor Medical Systems (ASX:IMR), the current Equity-to-Asset is 0.25 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Imricor Medical Systems (ASX:IMR) Overvalued in 2026?
Based on GuruFocus' analysis, Imricor Medical Systems stock appears to be overvalued.
The current stock price of A$1.86 is trading 1760% above its estimated GF Value™ of A$0.10.
GuruFocus considers Imricor Medical Systems to be Significantly Overvalued.
Key valuation signals for ASX:IMR:
Equity-to-Asset: 0.25 (59% below median its 10-year median of 0.61)
GF Value™: A$0.10 vs. price of A$1.86 (1760% above fair value)
Industry Position: 60.9% below the Medical Devices & Instruments median (#740 of 853)
No single metric tells the full story. See the ASX:IMR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Imricor Medical Systems Inc is a medical device company that develops MRI-guided technology to address issues with traditional X-ray ablation procedures. Its principal business activities are designing, manufacturing, and selling MRI-compatible products for cardiac catheter ablation procedures to treat arrhythmias. The company's products include the Advantage-MR EP Recorder/Stimulator, Vision-MR Ablation Catheter, and Vision-MR Dispersive Electrode. Geographically, the company generates maximum revenue from Europe.
42GF Score
Get the complete analysis for ASX:IMR
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:IMR has been successfully added to your 
